FierceBiotech6h
GSK plans to move vaccine R&D group from Maryland to the Boston area
After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...
Le Lézard8h
First Real-World Outcomes Data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO Genitourinary Cancers Symposium
Ferring Pharmaceuticals announced today three abstracts featuring ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented at the 2025 American Society of Clinical Oncologists Genitourinary ...
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
High BP may develop at different ages and paces in East & South Asian adults in the UK
A data analysis projected that South Asian adults living in the United Kingdom may experience elevated blood pressure nine ...
MaxCyte, Inc: MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery ...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...
Le Lézard2d
IVIEW Therapeutics Announces Topline Results from Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe for Dry Eye Disease
IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical ...